Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Revenue (PRX, CPD, HITK, AKRX)
Below are the top small-cap drugs-generic stocks on the NYSE, the NASDAQ and the AMEX in terms of revenue.
The trailing-twelve-month revenue at Pharmaceutical Companies (NYSE: PRX) is $1.01 billion. PRX's ROE for the same period is 16.46%.
The trailing-twelve-month revenue at Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) is $323.44 million. CPD had $63.69 million in total cash for the recent quarter.
The trailing-twelve-month revenue at Hi-Tech Pharmacal Co Inc (NASDAQ: HITK) is $175.84 million. HITK's PEG ratio is 0.69.
The trailing-twelve-month revenue at Akorn Inc (NASDAQ: AKRX) is $86.41 million. AKRX's ROE for the same period is 34.81%.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Drugs-Generic Industry Highest Revenue small-capSmall Cap Analysis Markets Trading Ideas
